Submission to Pharmac on Proposal to fund Ocrelizumab for Primary Progressive Multiple Sclerosis
Rare Disorders NZ has made a submission to Pharmac on the proposal to fund Ocrelizumab for Primary Progressive Multiple Sclerosis.
Rare Disorders NZ has been a long-time advocate for access to medicines for rare disorders, including rare forms of Multiple Sclerosis (MS).
Rare Disorders NZ supports the changes proposed to the Special Authority Criteria to include access for people with PPMS for Ocrelizumab specifically. We request the proposal is approved with no further delay.
Read the full submission here.